AstraZeneca PLC (AZN)vsHigh Tide Inc (HITI)
AZN
AstraZeneca PLC
$160.17
+2.23%
HEALTHCARE · Cap: $252.33B
HITI
High Tide Inc
$2.53
-1.17%
HEALTHCARE · Cap: $221.43M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 9041% more annual revenue ($61.37B vs $671.35M). AZN leads profitability with a 17.0% profit margin vs -6.6%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
HITI
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for HITI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 30.1% year-over-year
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Operating margin of 4.5%
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : HITI
The strongest argument for HITI centers on Revenue Growth. Revenue growth of 30.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : HITI
The primary concerns for HITI are Market Cap, Operating Margin, Debt/Equity. Debt-to-equity of 1.67 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while HITI is a hypergrowth play — different risk/reward profiles.
HITI carries more volatility with a beta of 1.04 — expect wider price swings.
HITI is growing revenue faster at 30.1% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 32/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
High Tide Inc
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
High Tide Inc. is a vertically integrated company in the cannabis market in Canada, the United States and internationally. The company is headquartered in Calgary, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?